<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-02-03</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-02-03 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">105</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-02-04 04:10</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-28">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/28</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-29">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/29</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-30">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/30</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-31">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/31</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-02-01">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">02/01</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-02">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">02/02</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-03">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">02/03</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºé‡ç£…è¯ç‰©ç ”å‘è¿›å±•ä¸ç›‘ç®¡å®¡æ‰¹ã€‚è¯ºå’Œè¯ºå¾·æ–°ä¸€ä»£ä»£è°¢è¯ç‰©CagriSemaåœ¨ç³–å°¿ç—…è¯•éªŒä¸­è¡¨ç°ä¼˜äºå¸ç¾æ ¼é²è‚½ï¼Œæˆä¸ºè‚¥èƒ–ç—‡/ç³–å°¿ç—…é¢†åŸŸçš„é‡è¦çªç ´ï¼›FDAå¯¹CAR-Tç–—æ³•ç”¨äºè‡ªèº«å…ç–«æ€§ç–¾ç—…å±•ç°å‡ºå®¡æ…æ”¯æŒæ€åº¦ï¼ŒåŒæ—¶é˜¿æ–¯åˆ©åº·çš®ä¸‹æ³¨å°„ç‰ˆç‹¼ç–®è¯ç‰©Saphneloé­FDAæ‹’ç»ï¼Œå‡¸æ˜¾ç›‘ç®¡å¤æ‚æ€§ã€‚æ­¤å¤–ï¼Œç¤¼æ¥å®£å¸ƒ35äº¿ç¾å…ƒæ–°å·¥å‚æŠ•èµ„ï¼Œå°åº¦æ”¿åºœæŠ•å…¥11äº¿ç¾å…ƒæ¨åŠ¨ç”Ÿç‰©åˆ¶å‰‚å‘å±•ï¼Œæ˜¾ç¤ºå…¨çƒäº§èƒ½å¸ƒå±€ä¸äº§ä¸šå‡çº§è¶‹åŠ¿ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>9. New CagriSema data show improvement over semaglutide</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - è¯ºå’Œè¯ºå¾·æ–°ä¸€ä»£ä»£è°¢è¯ç‰©CagriSemaåœ¨é™ç³–å‡é‡æ–¹é¢ä¼˜äºé‡ç£…è¯ç‰©å¸ç¾æ ¼é²è‚½ï¼Œå¯èƒ½é‡å¡‘è‚¥èƒ–ç—‡/ç³–å°¿ç—…æ²»ç–—æ ¼å±€</p>
<p><strong>1. FDA signals tailored approach to 'carefully shepherd' CAR-T therapy for autoimmune diseases</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAé¦–æ¬¡æ˜ç¡®æ”¯æŒCAR-Tç–—æ³•ç”¨äºè‡ªèº«å…ç–«æ€§ç–¾ç—…ï¼Œå¼€è¾Ÿäº†ç»†èƒæ²»ç–—æ–°åº”ç”¨é¢†åŸŸ</p>
<p><strong>19. Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in Pa.</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - ç¤¼æ¥æŠ•èµ„35äº¿ç¾å…ƒå»ºè®¾æ–°å·¥å‚ï¼Œå®Œæˆå…¶ç¾å›½åˆ¶é€ æ‰©å¼ è®¡åˆ’ï¼Œåº”å¯¹GLP-1è¯ç‰©éœ€æ±‚æ¿€å¢</p>
<p><strong>14. India will invest $1.1B to boost development of biologics, biosimilars</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - å°åº¦æ”¿åºœæŠ•å…¥11äº¿ç¾å…ƒæ¨åŠ¨ç”Ÿç‰©åˆ¶å‰‚å‘å±•ï¼Œæ ‡å¿—è¯¥å›½ä»ä»¿åˆ¶è¯å‘ç”Ÿç‰©åˆ¶è¯çš„æˆ˜ç•¥è½¬å‹</p>
<p><strong>15. FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - é˜¿æ–¯åˆ©åº·çš®ä¸‹æ³¨å°„ç‰ˆç‹¼ç–®è¯ç‰©é­FDAæ‹’ç»ï¼Œä½†å…¬å¸é¢„è®¡å¿«é€Ÿè§£å†³ï¼Œå½±å“é‡è¦äº§å“çº¿æ‰©å±•</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): è¯ºå’Œè¯ºå¾·CagriSemaåœ¨ç³–å°¿ç—…è¯•éªŒä¸­æ˜¾ç¤ºä¼˜äºå¸ç¾æ ¼é²è‚½çš„ç–—æ•ˆï¼›å®‰è¿›æ”¾å¼ƒæ¹¿ç–¹è¯ç‰©å¼€å‘ï¼›ä¸­å›½åŸºå› ç¼–è¾‘åˆåˆ›å…¬å¸AccurEditèèµ„7500ä¸‡ç¾å…ƒæ¨è¿›CRISPRç–—æ³•ï¼›Ultragenyxå…¬å¸ƒåŸºå› ç–—æ³•æ–°æ•°æ®æ”¯æŒé‡æ–°æäº¤ç”³è¯·ï¼›è¾‰ç‘æœˆåº¦GLP-1è¯ç‰©æ˜¾ç¤ºå‡é‡æ•ˆæœã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): CagriSemaåœ¨2å‹ç³–å°¿ç—…æ‚£è€…çš„IIIæœŸè¯•éªŒä¸­è¾¾åˆ°ä¸»è¦ç»ˆç‚¹ï¼›Argo Biopharmaçš„siRNAç–—æ³•BWâ€‘20829å¯åŠ¨IIbæœŸè¯•éªŒï¼›Kyowa Kirinåœ¨æ¹¿ç–¹è¯ç‰©IIIæœŸè¯•éªŒä¸­æŠ«éœ²å‰¯ä½œç”¨äº‹ä»¶ï¼›En Carta Diagnosticsçš„è±å§†ç—…æ£€æµ‹è®¾å¤‡è·FDAçªç ´æ€§è®¾å¤‡è®¤å®šã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>é‡ç‚¹å…³æ³¨FDAå¯¹CAR-Tç”¨äºè‡ªèº«å…ç–«æ€§ç–¾ç—…çš„å…·ä½“ç›‘ç®¡æ¡†æ¶ç»†èŠ‚ï¼›é˜¿æ–¯åˆ©åº·å¦‚ä½•å¿«é€Ÿè§£å†³Saphneloçš®ä¸‹æ³¨å°„ç‰ˆçš„å®¡æ‰¹é—®é¢˜ï¼›è¯ºå’Œè¯ºå¾·CagriSemaä¸ç¤¼æ¥Zepboundçš„å¸‚åœºç«äº‰æ€åŠ¿æ¼”å˜ï¼›å®‰è¿›Tavneosæ•°æ®å®Œæ•´æ€§å®¡æŸ¥çš„æœ€ç»ˆç»“æœåŠå…¶å¸‚åœºå½±å“ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">43 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA signals tailored approach to â€˜carefully shepherdâ€™ CAR-T therapy for autoimmune diseases
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 11:17</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDAâ€™s Vinay Prasad, M.D., and colleagues have signaled a willingness to support the development of these novel cell therapies with a flexible regulatory approach.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/fda-signals-tailored-approach-carefully-shepherd-car-t-therapy-autoimmune-diseases" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CHMP thumbs-up Novo&#39;s semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-30 11:35</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofi, Novo Nordisk, UCB and others received positive opinions from Europe&#39;s Committee for Medicinal Products for Human Use, while Amgen&#39;s approved Tavneos is up for a re-review due to data integrity concerns.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/europes-chmp-thumbs-novos-semaglutide-mash-sanofis-rezurock-and-more-while-amgens-tavneos" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CDMO Vetter maps out expansion in Germany with â‚¬480M for new plant
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 17:26</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/german-cdmo-vetter-takes-global-expansion-spree-its-home-country-eu480m-investment" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        India will invest $1.1B to boost development of biologics, biosimilars
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and biosimilars</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/india-will-invest-11b-boost-development-biologics-biosimilars" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA rejects AZ&#39;s subQ Saphnelo, but company expects quick turnaround for new approval decision
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 09:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca will have to negotiate what appears to be a minor speed bump in order to gain clearance in the U.S. for its subcutaneous version of lupus treatment Saphnelo. The FDA has rejected AZ&#39;s application that would allow patients to self-administer the monoclonal antibody in a prefilled pen. The advancement would give patients a convenient alternative to traveling to a doctor&#39;s office for infusions every four weeks.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        With FDA rejections, Aquestive&#39;s shares go up, while Pharming&#39;s go down
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 11:15</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-rejections-aquestives-shares-go-while-pharmings-go-down" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 10:02</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid an outpouring of industry investments in U.S. drug production, the FDA has launched a new program designed to reduce the complexities involved in setting up domestic manufacturing plants.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-emphasizes-drug-ingredients-production-pledges-it-debuts-precheck-manufacturing-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A sales turnaround for Regeneron&#39;s Eylea franchise will have to wait at least another quarter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-30 11:15</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">For the last several quarters, declining sales of Regeneron&#39;s eye disease treatment Eylea have exceeded increasing sales of the drug&#39;s new version, Eylea HD, leading to a steady decline in overall U.S. sales for the Eylea franchise. The company said Friday the trend will continue in the first quarter of this year.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/turnaround-regenerons-eylea-will-have-wait-least-another-quarter" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in Pa.
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-30 09:19</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvaniaâ€™s Lehigh Valley, rounding out the quartet of plants it promised during its â€œLilly in Americaâ€ investment announcement last year.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:28</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 16:03</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about AstraZeneca investing in China, an abandoned overdose antidote, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 14:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/29/astrazeneca-hologen-kickbacks-overdose-lilly-china/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BMS, J&amp;amp;J factor in HCP education on clot-busting mechanism before milvexian data drop
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 09:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bristol Myers Squibb and Johnson &amp;amp; Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bms-jj-factor-physician-education-clot-busting-mechanism-x-factor-readouts" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fierce Pharma Asiaâ€”AZ&#39;s $15B China investment; Boehringer, Simcere&#39;s IBD deal; Daiichi&#39;s ADC growth push
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 15:08</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel disease bispecific from Simcere. Daiichi Sankyo&#39;s U.S. chief talked about the successâ€”and challengesâ€”the company is seeing with Enhertu and Datroway. And more.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/az-15b-china-investment-boehringer-simcere-ibd-deal-daiichi-adc-growth-push" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HHS launches $100M antiviral prize to develop broad-spectrum therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 14:39</span>
                        
                    </div>
                    
                    <p class="news-summary">While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/hhs-launches-100-million-antiviral-prize-develop-broad-spectrum-therapies" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo shares plummet on sales, profit warning for &#39;26 as 2 top execs head for the doors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 13:39</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales and earnings declines in 2026.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Charles River to close cell therapy CDMO site, lay off 20 staffers
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.</p>
                    
                    <a href="https://www.fiercepharma.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 11:43</span>
                        
                    </div>
                    
                    <p class="news-summary">As top-selling Keytruda inches closer to its 2028 patent cliff, Merck&#39;s confidence in sustainable growth for the future is &#34;as high as it&#39;s ever been,&#34; CEO Robert Davis said on the company&#39;s full-year 2025 earnings call.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi sanctioned by PMCPA over CEO&#39;s &#39;bold claims&#39; about Pfizer RSV vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 05:34</span>
                        
                    </div>
                    
                    <p class="news-summary">A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. governmentâ€™s vaccine program by making â€œbold claimsâ€ about a procurement choice.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie has â€˜Love in Mindâ€™ with new migraine educational campaign
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 12:11</span>
                        
                    </div>
                    
                    <p class="news-summary">With Valentineâ€™s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new campaign focusing on how migraines can impact romantic relationships.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/abbvie-has-love-mind-new-migraine-educational-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thermo Fisher trims Massachusetts headcount with Franklin site closure
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 11:06</span>
                        
                    </div>
                    
                    <p class="news-summary">Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site itâ€™s shuttering in Franklin, Massachusetts, which currently employs about 200 people.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/thermo-fisher-trims-massachusetts-headcount-franklin-site-closure" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Why human expertise still matters in AI-driven med comms
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 16:32</span>
                        
                    </div>
                    
                    <p class="news-summary">RTI Health Solutions experts explain how AI can help medical communications without replacing rigor, judgment or trust.</p>
                    
                    <a href="https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump administration officials are at loggerheads over future of COVID vaccines: Axios
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-30 06:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Some officials in the Trump administration are at odds with others who are helping shape vaccine policy over whether to remove COVID vaccines from the U.S. market, according to a report from Axios.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trump-administration-officials-are-loggerheads-over-covid-vaccines-report" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Quince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-30 09:57</span>
                        
                    </div>
                    
                    <p class="news-summary">Quince Therapeuticsâ€™ novel method of delivering steroids in a patientâ€™s own red blood cells turned out to be a bust in ataxia-telangiectasia, a rare inherited disorder, with the company now planning to â€œpreserve cash and explore available options.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/quince-therapeutics-teeters-edge-steroid-blood-cell-fails-rare-genetic-disease" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biopharma&#39;s rebound keeping pace so far
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 15:56</span>
                        
                    </div>
                    
                    <p class="news-summary">This week on &#34;The Top Line,&#34; we explore biopharma&#39;s rebound, dealmaking momentum and what&#39;s cutting through the noise in 2026.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/biopharmas-rebound-keeping-pace-so-far" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 14:36</span>
                        
                    </div>
                    
                    <p class="news-summary">On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk&#39;s challenge of drug pricing provisions in the Inflation Reduction Act. As with other challenges to the IRA, the Chamber argued that the negotiations baked into the law are â€œillusory.&#34;</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novo-gets-chamber-commerce-backing-bid-bring-ira-challenge-supreme-court" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 17:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer unveils data on Metsera drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:41</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer moves forward with its hopes for a monthly obesity drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 12:22</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing increasingly competitive.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: As U.S. officials move to reduce animal testing in research, focus may shift to restrictions on imports
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration is seeking to reduce animal testing in research. Some activists are pushing the administration to suspend primate imports for research purposes entirely.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/animal-lab-research-imports-kennedy/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: A play takes on Novoâ€™s myth and money
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 14:51</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 13:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: As its immunology work draws attention, Sanofi also pushes forward in rare disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 06:00</span>
                        
                    </div>
                    
                    <p class="news-summary">An experimental Sanofi drug helped improve the neurological problems seen with a rare disease, as the company plans to seek approval.</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/sanofi-venglustat-gaucher-rare-disease-neurological-symptoms/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 17:06</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/30/pharma-biotech-jobs-abbvie-merck-biontech-moderna-takeda-novo/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: New rule would force PBMs to disclose drug rebates and other fees
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 15:48</span>
                        
                    </div>
                    
                    <p class="news-summary">The proposal would mark a significant change for the secretive PBM industry, which often shields crucial data from its clients.</p>
                    
                    <a href="https://www.statnews.com/2026/01/30/pbm-drug-rebate-transparency-proposed-rule-department-of-labor/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: AstraZeneca looks to China for obesity drug candidates
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 14:36</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/30/biotech-news-astrazeneca-china-obesity-drug-candidates/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about TrumpRx questions, drugmakers lowering some prices, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 14:35</span>
                        
                    </div>
                    
                    <p class="news-summary">Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx â€” whose structure has yet to be detailed</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/30/trump-telehealth-obesity-pbm-insulin-astrazeneca-china/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: States are the next vaccine battleground
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 17:07</span>
                        
                    </div>
                    
                    <p class="news-summary">This is the web edition of STAT&#39;s D.C. Diagnosis newsletter.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 16:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Trump wants lawmakers to force pharma companies to lower their prices, but it&#39;s not clear the GOP is on board.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: How Opvee, Indiviorâ€™s powerful overdose antidote, went bust
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Opvee reverses opioid overdose more quickly than Narcan. It also can cause withdrawal symptoms. Harm reduction advocates fought it, and won.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/why-opvee-overdose-antidote-failed-harm-reduction-community-opposition/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Eli Lilly expands work on gene therapies for hearing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 14:49</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:51</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer took a write-down on one of its recent high-profile acquisitions while reporting a positive readout from another. The pharma giant said on Tuesday it took a $4.4 billion impairment charge related in part to ...</p>
                    
                    <a href="https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:03</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...</p>
                    
                    <a href="https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 20:42</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The first 10 drugs that underwent government price negotiations in 2023 were projected to save the government billions of dollars. Now, one month since the new pricing took effect, the extent to which those savings ...</p>
                    
                    <a href="https://endpoints.news/first-10-medicare-negotiated-drug-prices-have-taken-effect-are-seniors-really-saving-money/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Amgen gives up on its once-prized eczema drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-30 16:57</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/amgen-return-rocatinlimab-kyowa-kirin-atopic-dermatitis-eczma-ox40/810964/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        New CagriSema data show improvement over semaglutide
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 19:16</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordiskâ€™s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes. That was the topline result from the latest Phase 3 readout ...</p>
                    
                    <a href="https://endpoints.news/new-cagrisema-data-show-improvement-over-semaglutide/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 15:22</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news on AstraZeneca, Johnson &amp;amp; Johnson, Averin Capital and Chugai: ğŸ§ª Kyowa Kirin discloses side effect for recently regained drug: A patient participating in a Phase 3 trial to treat eczema developed a case ...</p>
                    
                    <a href="https://endpoints.news/kyowa-kirin-reveals-side-effect-in-trial-gsk-was-lone-bidder-for-rapt/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA launches â€˜PreCheckâ€™ program; AstraZeneca, Acadia drugs set back
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-03 15:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The agency&amp;rsquo;s program will be open to pharmaceutical facilities that align with &amp;ldquo;national priorities.&amp;rdquo; Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.</p>
                    
                    <a href="https://www.biopharmadive.com/news/fda-precheck-astrazeneca-acadia-reject-meiragtx/811092/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo combination obesity shot meets goal in diabetes trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 19:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CagriSema&amp;rsquo;s blood sugar and weight reductions exceeded the company&amp;rsquo;s blockbuster Wegovy, yet the drug might still struggle to rival Lilly&#39;s Zepbound.</p>
                    
                    <a href="https://www.biopharmadive.com/news/novo-cagrisema-diabetes-reimagine-study-results/811115/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca leans into obesity, striking wide-ranging alliance with Chinaâ€™s CSPC
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-30 12:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The deal, which involves up to eight &amp;ldquo;next-generation&amp;rdquo; weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.</p>
                    
                    <a href="https://www.biopharmadive.com/news/astrazeneca-obesity-deal-china-cspc-ai/810942/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Politicization runs deeper than ever at FDA, risking long-term impacts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-30 12:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration&amp;rsquo;s political agenda, according to an economist and public policy expert.</p>
                    
                    <a href="https://www.biopharmadive.com/news/fda-politicization-deeper-than-ever-risking-long-term-impacts/810909/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA seeks withdrawal of Amgen&#39;s Tavneos, company says it won&#39;t pull drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 00:48</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Several years of questions about Amgen&#39;s rare disease treatment Tavneos have come to a climax after the FDA asked the company to pull the drug from the market, and Amgen said it has no plans ...</p>
                    
                    <a href="https://endpoints.news/fda-seeks-withdrawal-of-amgens-tavneos-company-says-it-wont-pull-drug/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UKâ€™s health department expected to spend Â£1B in pharma trade deal with US
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 00:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The UK&#39;s drug pricing deal with the White House is expected to cost Â£1 billion between 2026 and 2029, according to a letter from the country&#39;s science minister. The letter was published Wednesday morning by ...</p>
                    
                    <a href="https://endpoints.news/uks-health-department-expected-to-spend-1b-in-pharma-trade-deal-with-us/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s driving health tech M&amp;A
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 16:28</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The past week saw a flurry of health tech acquisitions (we counted at least five!). Part of the rush of activity is seasonal â€” the end of the year often serves as a ...</p>
                    
                    <a href="https://endpoints.news/whats-driving-health-tech-ma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China startup AccurEdit raises $75M for gene editing therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 16:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AccurEdit Therapeutics, a startup based in Suzhou, China, has raised $75 million in Series A funding to advance its growing pipeline of CRISPR-based medicines â€” among the largest rounds on record for a Chinese gene editing ...</p>
                    
                    <a href="https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ultragenyx unwraps data that may be central to its gene therapy resubmission
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 13:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Ultragenyx outlined new data on Tuesday that it hopes will convince the FDA to approve its recently resubmitted rare disease gene therapy. Among 17 patients with Sanfilippo syndrome type A who received the therapy, cognition ...</p>
                    
                    <a href="https://endpoints.news/ultragenyx-unwraps-data-that-may-be-central-to-its-gene-therapy-resubmission/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: Do Pfizerâ€™s monthly GLP-1 data justify Metseraâ€™s $10B price tag?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on ...</p>
                    
                    <a href="https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA rejects Aquestive&#39;s allergy drug over packaging issues
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 15:17</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has delivered a complete response letter to Aquestive Therapeutics for its allergy medication due to issues over the drugâ€™s packaging. The agency declined to approve Aquestiveâ€™s allergy patch called Anaphylm in patients weighing ...</p>
                    
                    <a href="https://endpoints.news/fda-rejects-aquestives-allergy-drug-over-packaging-issues/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA opens submissions for PreCheck program to speed up US factory builds
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 14:46</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has started accepting pitches for drugmakers to participate in the agencyâ€™s PreCheck program, a new initiative aimed to speed up the construction of US manufacturing sites. The agency</p>
                    
                    <a href="https://endpoints.news/fda-opens-submissions-for-precheck-program-to-speed-up-us-factory-builds/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pharmingâ€™s immunodeficiency drug gets CRL for use in younger patients
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 11:52</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has issued a complete response letter to Pharming, rejecting its attempt to expand the approval of its drug for a rare form of immunodeficiency into younger patients. Joenja was</p>
                    
                    <a href="https://endpoints.news/pharmings-immunodeficiency-drug-gets-crl-for-use-in-younger-patients/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer dips on new data for obesity drug acquired in $10B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-03 17:01</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A long-acting shot Pfizer got through a buyout of Metsera appeared &amp;ldquo;slightly inferior&amp;rdquo; to Lilly&amp;rsquo;s market-leading Zepbound in a Phase 2 trial, one analyst said.</p>
                    
                    <a href="https://www.biopharmadive.com/news/pfizer-obesity-metsera-phase-2-results-GLP1-monthly-shot/811201/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofiâ€™s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 12:12</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofiâ€™s investigational drug, with a track record of mixed results in the clinic, has passed a Phase 3 trial in Gaucher disease, but flunked a separate late-stage study in Fabry disease.</p>
                    
                    <a href="https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 17:12</span>
                        
                    </div>
                    
                    <p class="news-summary">The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.</p>
                    
                    <a href="https://www.biopharmadive.com/news/sanofi-venglustat-gaucher-fabry-study-results/811113/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK walks away from pioneering Wave RNA editing drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 13:31</span>
                        
                    </div>
                    
                    <p class="news-summary">Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.</p>
                    
                    <a href="https://www.biopharmadive.com/news/wave-gsk-reacquire-rna-editing-drug-aatd/811067/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Building a robust in-process testing plan for cell therapy manufacturing success
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 10:00</span>
                        
                    </div>
                    
                    <p class="news-summary">The roadmap to reliable inâ€‘process testing for cell therapy success.</p>
                    
                    <a href="https://www.biopharmadive.com/spons/building-a-robust-in-process-testing-plan-for-cell-therapy-manufacturing-su/810800/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The biopharma industry outlook on 2026: Optimism and tension
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-29 19:31</span>
                        
                    </div>
                    
                    <p class="news-summary">A spike in M&amp;amp;A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector&#39;s resurgence.</p>
                    
                    <a href="https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo expects sales to fall in 2026, triggering selloff
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 20:07</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk expects its sales to shrink by at least 5% this year, citing negative pricing dynamics, including its deal with the US government. The Danish pharma said in its</p>
                    
                    <a href="https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &#39;Turning around the Titanic&#39;: How the incoming PBM reforms will transform CMS
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 19:34</span>
                        
                    </div>
                    
                    <p class="news-summary">The Centers for Medicare and Medicaid Services has never played a significant role in regulating pharmacy benefit managers, the middlemen that have historically relied on high drug prices for profits. But the government spending package ...</p>
                    
                    <a href="https://endpoints.news/turning-around-the-titanic-how-the-incoming-pbm-reforms-will-transform-cms/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Daiichi ends work on an ADC; Layoffs at GSK&#39;s R&amp;D unit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 15:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Acadia Pharmaceuticals, Eli Lilly, PepLib Biotech, MeiraGTx, ZipBio, SantÃ© Ventures, Adlai Nortye, NMD Pharma, Eton Pharmaceuticals, vTv Therapeutics and Newsoara: âœ‚ï¸ Daiichi Sankyo culls next-gen ADC: Citing a strategic portfolio review ...</p>
                    
                    <a href="https://endpoints.news/daiichi-ends-work-on-an-adc-layoffs-at-gsks-rd-unit/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Menlo and a16z back AI scientist startup Phylo
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Within days of defending their PhDs last year, two Stanford University researchers incorporated their own startup, betting they could build a business around their AI system that handles scientific tasks. The Bay Area startup, called ...</p>
                    
                    <a href="https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Carbon Health files for bankruptcy, seeking to sell or restructure
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 21:22</span>
                        
                    </div>
                    
                    <p class="news-summary">Carbon Health has filed for bankruptcy protection and is seeking to restructure or sell itself, the urgent and primary care startup said Monday. The company voluntarily filed for Chapter 11 in the US Bankruptcy Court ...</p>
                    
                    <a href="https://endpoints.news/carbon-health-files-for-bankruptcy-seeking-to-sell-or-restructure/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK returns rights to Wave&#39;s RNA editing program for AATD
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 16:06</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK no longer plans to collaborate on a closely-watched RNA editing program from Wave Life Sciences, whose fate could influence the prospects of the emerging field. Wave announced Monday that GSK ...</p>
                    
                    <a href="https://endpoints.news/gsk-returns-rights-to-waves-rna-editing-program-for-aatd/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Spring Health acquires Alma, expanding insurance reach in virtual mental health
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 15:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Spring Health is the latest virtual mental health company to lean into insurance as it acquires competitor Alma. The deal, announced Thursday, would give Spring, which has traditionally focused on providing mental health services as ...</p>
                    
                    <a href="https://endpoints.news/spring-health-acquires-alma-expanding-insurance-reach-in-virtual-mental-health/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        SanegeneBio licenses RNAi candidate to Genentech for $200M upfront
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 14:35</span>
                        
                    </div>
                    
                    <p class="news-summary">Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B. The Roche unit will pay $200 million upfront for the global ...</p>
                    
                    <a href="https://endpoints.news/sanegenebio-licenses-rnai-candidate-to-genentech-for-200m-upfront/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        European law changes mean drugmakers may have to grapple with generic competition sooner
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 06:00</span>
                        
                    </div>
                    
                    <p class="news-summary">European regulators will soon sign in a new raft of laws that could make drugmakers jump through more hoops to delay generic and biosimilar competition. And companies developing rare disease and orphan drugs are likely ...</p>
                    
                    <a href="https://endpoints.news/imminent-european-law-changes-mean-drugmakers-may-have-to-grapple-with-generic-competition-sooner/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:18</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The US sees around 476,000 new Lyme cases every year</p>
                    
                    <a href="https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-28 14:20</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">siRNA therapeutic progresses in global study for patients with elevated Lp(a)</p>
                    
                    <a href="https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IBSA UK&amp;I launches Perovial for the treatment of acute Peyronieâ€™s disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease</p>
                    
                    <a href="https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CERo reports encouraging early data from phase 1 trial of CERâ€‘1236
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-29 10:59</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CERâ€‘T therapy shows initial safety signals and prompts protocol expansion</p>
                    
                    <a href="https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-29 10:44</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections</p>
                    
                    <a href="https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:43</span>
                        
                    </div>
                    
                    <p class="news-summary">The company will initially develop a vaccine to tackle colorectal and pancreatic cancers</p>
                    
                    <a href="https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys</p>
                    
                    <a href="https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Akari files new patent and advances second ADC targeting CEACAM5
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-28 14:15</span>
                        
                    </div>
                    
                    <p class="news-summary">Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate</p>
                    
                    <a href="https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA Rare Disease Innovation Hub
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 22:19</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.</p>
                    
                    <a href="http://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Summary Metrics of Drug Development Tool Qualification Projects Submitted to FDA
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 19:33</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This Table provides the current number of active CDER Drug Development Tool (DDT) Qualification projects overall and by Program (DDT- Animal Model Qualification Program, DDT- Biomarker Qualification Program, DDT- Clinical Outcomes Assessment [COA] Qualification Program). Numbers are also provided by</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/summary-metrics-drug-development-tool-qualification-projects-submitted-fda" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 14:22</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">ORA and CDER agree to replace and/or withdraw CPGs in favor of using guidance or procedural documents, as appropriate per GGP regulations.</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-130300-fda-access-results-quality-assurance-program-audits-and-inspections" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 13:09</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 21:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Prescription Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 19:47</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 20:59</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        National Drug Code Directory
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 20:29</span>
                        
                    </div>
                    
                    <p class="news-summary">National Drug Code Directory</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 19:17</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        PDUFA and BsUFA Quarterly Hiring Updates
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 15:06</span>
                        
                    </div>
                    
                    <p class="news-summary">PDUFA and BsUFA Quarterly Hiring Updates</p>
                    
                    <a href="http://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-and-bsufa-quarterly-hiring-updates" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cohance Lifesciences Limited - 718812 - 01/30/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">CGMP/Finished Pharmaceuticals/Adulterated</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cohance-lifesciences-limited-718812-01302026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HTO Nevada, Inc. dba Kirkman - 719074 - 01/27/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">CGMP/Finished Pharmaceuticals/Adulterated</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hto-nevada-inc-dba-kirkman-719074-01272026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Executive Order 14017 on Americaâ€™s Supply Chains
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-03 13:44</span>
                        
                    </div>
                    
                    <p class="news-summary">Updates on recommendations to help shore up the U.S. pharmaceutical supply chain, as directed by Executive Order 14017 on Americaâ€™s Supply Chains</p>
                    
                    <a href="http://www.fda.gov/about-fda/reports/executive-order-14017-americas-supply-chains" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pain and Arthritis Products Containing Hidden Ingredients
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 21:24</span>
                        
                    </div>
                    
                    <p class="news-summary">Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.</p>
                    
                    <a href="http://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Umary contains hidden drug ingredients
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 21:23</span>
                        
                    </div>
                    
                    <p class="news-summary">The Food and Drug Administration is advising consumers not to purchase or use Umary, a product promoted and sold for pain on various websites, including https://www.solovital.com and possibly in some retail stores.</p>
                    
                    <a href="http://www.fda.gov/drugs/medication-health-fraud-notifications/umary-contains-hidden-drug-ingredients" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Electronic Registration and Listing Compliance Program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 21:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).</p>
                    
                    <a href="http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Human Drug Compounding
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 21:17</span>
                        
                    </div>
                    
                    <p class="news-summary">Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.</p>
                    
                    <a href="http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eurosirel S.P.A - 690733 - 01/26/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 19:20</span>
                        
                    </div>
                    
                    <p class="news-summary">CGMP/Finished Pharmaceuticals/Adulterated</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-01262026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eurosirel S.P.A - 690733 - 11/20/2024
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 19:18</span>
                        
                    </div>
                    
                    <p class="news-summary">CGMP/Finished Pharmaceuticals/Adulterated</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-11202024" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        RDEA Pilot Program Disclosure Agreement | Rare Disease Endpoint Advancement Pilot Program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-02 17:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Disclosure Agreement | Rare Disease Endpoint Advancement Pilot Program</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/rdea-pilot-program-disclosure-agreement-rare-disease-endpoint-advancement-pilot-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-02-04 04:10</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>